Search

Displaying results 3231 - 3240 of 10000 in total
  1. Drug

    Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB19322
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  2. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB19323
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  3. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB19324
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  4. Drug

    Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole

    go.drugbank.com/drugs/DB19413
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  5. Drug

    Mequitazine

    go.drugbank.com/drugs/DB01071
    Investigational

    It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. … It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract.

  6. Drug

    Black cohosh

    go.drugbank.com/drugs/DB13975
    Approved

    in treating the symptoms of sleep and mood disturbance, and hot flushes. … [L2303] Hormone replacement therapy (HRT) is the standard treatment for early symptoms in post-menopausal women, however, increases the risk of stroke, heart diseases, as well as breast cancer in older

  7. Drug

    DS-2325a

    go.drugbank.com/drugs/DB18134
    Investigational

    DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

  8. Drug

    Guanadrel

    go.drugbank.com/drugs/DB00226
    Approved

    Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.

  9. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment

  10. Drug

    Anthoxanthum odoratum

    go.drugbank.com/drugs/DB14163
    Approved

    Anthoxanthum odoratum allergenic extract is used in allergenic testing.